Literature DB >> 32314234

Organ Preservation in Rectal Cancer.

Jonathan B Yuval1, Hannah M Thompson1, Julio Garcia-Aguilar2.   

Abstract

A proportion of patients with rectal cancer who undergo neoadjuvant treatment end up with a complete pathological response. Because these patients have excellent oncological outcomes, many have questioned if surgical treatment in this population constitutes overtreatment. There is growing interest in watch and wait with selective organ preservation for rectal cancer patients. We review the fundamentals and key considerations of this approach including patient selection, available treatment regimens, assessment of response, long-term monitoring of response, and long-term oncological and functional outcomes.

Entities:  

Keywords:  Nonoperative management; Organ preservation; Rectal cancer; Watch-and-wait

Mesh:

Year:  2020        PMID: 32314234      PMCID: PMC7390702          DOI: 10.1007/s11605-020-04583-w

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  53 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.

Authors:  Julio Garcia-Aguilar; Qian Shi; Charles R Thomas; Emily Chan; Peter Cataldo; Jorge Marcet; David Medich; Alessio Pigazzi; Samuel Oommen; Mitchell C Posner
Journal:  Ann Surg Oncol       Date:  2011-07-14       Impact factor: 5.344

3.  RADIATION IN THE TREATMENT OF RECTAL CANCER.

Authors:  G E Binkley
Journal:  Ann Surg       Date:  1929-12       Impact factor: 12.969

4.  Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.

Authors:  Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila
Journal:  Lancet Oncol       Date:  2015-07-14       Impact factor: 41.316

5.  Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study.

Authors:  Salvatore Pucciarelli; Paola Del Bianco; Fabio Efficace; Samantha Serpentini; Carlo Capirci; Antonino De Paoli; Antonio Amato; Dajana Cuicchi; Donato Nitti
Journal:  Ann Surg       Date:  2011-01       Impact factor: 12.969

Review 6.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

7.  Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.

Authors:  In Ja Park; Y Nancy You; Atin Agarwal; John M Skibber; Miguel A Rodriguez-Bigas; Cathy Eng; Barry W Feig; Prajnan Das; Sunil Krishnan; Christopher H Crane; Chung-Yuan Hu; George J Chang
Journal:  J Clin Oncol       Date:  2012-04-09       Impact factor: 44.544

8.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

Authors:  Monique Maas; Patty J Nelemans; Vincenzo Valentini; Prajnan Das; Claus Rödel; Li-Jen Kuo; Felipe A Calvo; Julio García-Aguilar; Rob Glynne-Jones; Karin Haustermans; Mohammed Mohiuddin; Salvatore Pucciarelli; William Small; Javier Suárez; George Theodoropoulos; Sebastiano Biondo; Regina G H Beets-Tan; Geerard L Beets
Journal:  Lancet Oncol       Date:  2010-08-06       Impact factor: 41.316

9.  Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial.

Authors:  Tina Yen-Ting Chen; Lisette M Wiltink; Remi A Nout; Elma Meershoek-Klein Kranenbarg; Søren Laurberg; Corrie A M Marijnen; Cornelis J H van de Velde
Journal:  Clin Colorectal Cancer       Date:  2014-12-31       Impact factor: 4.481

10.  Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.

Authors:  J Joshua Smith; Oliver S Chow; Marc J Gollub; Garrett M Nash; Larissa K Temple; Martin R Weiser; José G Guillem; Philip B Paty; Karin Avila; Julio Garcia-Aguilar
Journal:  BMC Cancer       Date:  2015-10-23       Impact factor: 4.430

View more
  6 in total

1.  A Pilot, Prospective, Observational Study to Investigate the Value of NGS in Liquid Biopsies to Predict Tumor Response After Neoadjuvant Chemo-Radiotherapy in Patients With Locally Advanced Rectal Cancer: The LiBReCa Study.

Authors:  Raffaello Roesel; Samantha Epistolio; Francesca Molinari; Piercarlo Saletti; Sara De Dosso; Mariacarla Valli; Alessandra Franzetti-Pellanda; Letizia Deantonio; Maira Biggiogero; Paolo Spina; Sotirios Georgios Popeskou; Alessandra Cristaudi; Francesco Mongelli; Luca Mazzucchelli; Federico Mattia Stefanini; Milo Frattini; Dimitri Christoforidis
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

2.  Does restaging MRI radiomics analysis improve pathological complete response prediction in rectal cancer patients? A prognostic model development.

Authors:  Giuditta Chiloiro; Davide Cusumano; Paola de Franco; Jacopo Lenkowicz; Luca Boldrini; Davide Carano; Brunella Barbaro; Barbara Corvari; Nicola Dinapoli; Martina Giraffa; Elisa Meldolesi; Riccardo Manfredi; Vincenzo Valentini; Maria Antonietta Gambacorta
Journal:  Radiol Med       Date:  2021-11-01       Impact factor: 3.469

Review 3.  Watch-and-wait Management for Rectal Cancer After Clinical Complete Response to Neoadjuvant Therapy.

Authors:  Jonathan B Yuval; Julio Garcia-Aguilar
Journal:  Adv Surg       Date:  2021-07-06

Review 4.  Role of MRI‑based radiomics in locally advanced rectal cancer (Review).

Authors:  Siyu Zhang; Mingrong Yu; Dan Chen; Peidong Li; Bin Tang; Jie Li
Journal:  Oncol Rep       Date:  2021-12-22       Impact factor: 3.906

5.  The "Immunoscore" in rectal cancer: could we search quality beyond quantity of life?

Authors:  Amos Kirilovsky; Carine El Sissy; Guy Zeitoun; Florence Marliot; Nacilla Haicheur; Christine Lagorce-Pagès; Julien Taieb; Mehdi Karoui; Petra Custers; Edina Dizdarevic; Soledad Iseas; Torben Frøstrup Hansen; Lars Henrik Jensen; Geerard Beets; Jean Pierre Gérard; Mireia Castillo-Martin; Nuno Figueiredo; Angelita Habr-Gama; Rodrigo Perez; Jérôme Galon; Franck Pagès
Journal:  Oncotarget       Date:  2022-01-05

6.  Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).

Authors:  Takashi Akiyoshi; Eiji Shinozaki; Senzo Taguchi; Akiko Chino; Makiko Hiratsuka; Tetsuro Tominaga; Takashi Nonaka; Shigeo Toda; Shuichiro Matoba; Shimpei Matsui; Koji Okabayashi; Toshiki Mukai; Yukiharu Hiyoshi; Tomohiro Yamaguchi; Toshiya Nagasaki; Kensei Yamaguchi; Masashi Ueno; Hiroya Kuroyanagi; Yosuke Fukunaga; Naoki Ishizuka; Tsuyoshi Konishi
Journal:  BMJ Open       Date:  2022-03-18       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.